CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
The proposed study is of a Liposomal formulation of cytarabine and daunorubicin (CPX-351) in
patients treated for higher-risk myelodysplastic syndromes (MDS) experiencing hypomethylating
agent failure.